Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Zim Laboratories Ltd

Zim Laboratories | 541400

Market Closed
₹147.80
₹1.03 (-0.69%)
As on 23/11/26, 2:56 AM
Market Cap798.55 CR
Current Price₹147.8
High / Low₹159.81 / 59.31
PE Ratio54.93
Book Value₹54.9
Dividend Yield0.00%
ROCE4.76%
ROE1.66%
Face Value₹2.00
Current Vol.1,36,901
Average Vol.---
ISININE518E01015
PB Ratio1.09
Debt to Equity0.45
Net Profit Margin1.16
Operating Margin10.37

ZIMLAB - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹148.82₹148
₹147.8
Previous CloseToday's Open
₹59.31₹159.81
₹147.8
52W Low52W High
₹148Today's Open
₹148.82Previous Close
1,36,901Volume
₹59.3152W Low
₹159.8152W High

Ratios

No data available

About Company

  • Zim Laboratories Limited was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in Maharashtra
  • The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Mumbai
  • The Company commenced its operations in 1989 and is a specialist firm focused on the developing, manufacturing, and global distribution of differentiated generic Pharmaceutical and Nutraceutical products in oral solid dosage forms
  • The Company's comprehensive services include both PreFormulation Intermediates (PFI) and Finished Formulations (FF) across numerous vital therapeutic areas globally
  • Company's core therapeutic focus areas include: Urology, Gastrointestinal, NSAIDs / Analgesics, Anti-infectives, Cardiovascular, Central Nervous System, and Vitamins & Supplements
  • ZIM acts as a key supplier of both finished and semi-finished products within its targeted markets
  • ZIM operates three state-of-the-art manufacturing facilities i
  • General, Cephalosporin, and OTF and a well-established R&D centre, all staffed by highly skilled professionals
  • During the year 2019-20, ZIM Health Technologies Limited was acquired, making it a wholly owned subsidiary of the Company
  • SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI59.43
SMA 20137.53
SMA 50138.00
SMA 100128.38
SMA 200107.28
SMA 10139.59
MACD_12_26_Days1.80
EMA10Day140.79
EMA20Day139.03
EMA50Day135.62
MACD_12_26_9_Days1.08
EMA100Day127.70
EMA200Day115.01

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth-1.22%
ROE1.59%
EBITDA Margin10.37%

All figures in ₹ Crores

Indicators20262025202420232022
Revenue
374.40
379.03
367.42
398.53
333.43
Interest
13.20
11.39
6.92
5.58
8.31
Expenses
344.39
335.30
326.09
346.54
292.45
Financing Profit
41.39
49.51
46.52
58.40
45.38
Financing Margin %
11%
13%
13%
15%
14%
Other Income
11.38
5.78
5.18
6.41
4.40
Depreciation
19.98
20.11
15.95
17.47
16.03
Profit before tax
8.21
18.01
23.64
35.35
21.04
Tax %
29%
32%
27%
31%
31%
Net Profit
5.84
12.16
17.25
24.43
14.55
EPS in Rs
1.19
2.50
3.54
5.01
2.99
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
29 Jun 2026
AGM
AGM
05 Jun 2026
16 Feb 2026
EGM
EGM
21 Jan 2026
27 Jun 2025
AGM
AGM
03 Jun 2025
27 Jun 2024
AGM
AGM
06 Jun 2024
10 Jul 2023
AGM
AGM
15 Jun 2023
22 Dec 2022
Bonus Issue (2:1)
2:1 Bonus Issue of Equity Shares
12 Dec 2022
12 Dec 2022
EGM
EGM
12 Nov 2022
19 Sept 2022
AGM
AGM
29 Aug 2022
29 Jun 2022
EGM
EGM
06 Jun 2022

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
148
794
379
3
33
0
1.16%
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 140 Results

Frequently Asked Questions

What is Share Price of Zim Laboratories Ltd?

The current share price of Zim Laboratories Ltd (Zim Laboratories) is ₹147.80. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Zim Laboratories Ltd?

The Price-to-Earnings (P/E) ratio of Zim Laboratories Ltd is 385.51. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Zim Laboratories Ltd?

Zim Laboratories Ltd has a 52-week high of ₹159.81 and a 52-week low of ₹59.31. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Zim Laboratories Ltd?

Zim Laboratories Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Zim Laboratories Ltd?

The Earnings Per Share (EPS) of Zim Laboratories Ltd is ₹0.39. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Zim Laboratories Ltd?

Zim Laboratories Ltd has a Return on Equity (ROE) of 1.66%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2